UNSPSC 51342400: Antiviral isoquinolines

Antiviral drugs made from a group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine.

UNSPSC 51342400 Antiviral isoquinolines is a Class code that shows minimal relevant recent activity aligned with its stated scope. State and local procurement records tagged with this code reveal a substantial mismatch between the abstract pharmaceutical classification and the work actually being solicited. Of the four recent opportunities in the data, none directly procure antiviral isoquinoline compounds; instead, they span naloxone (an opioid antagonist unrelated to antivirals), generic multi-source pharmaceuticals and OTC products via cooperative purchasing, direct-to-manufacturer prescription program strategy consulting, and general medical and first aid supplies for fire department rescue operations. The issuing bodies include a county health department (Seminole County, Florida), a state health agency (Texas HHS Commission), a municipal purchasing office (City of Tampa), and a multi-state cooperative (MMCAP administered by Minnesota Department of Administration). The code's sparse and off-scope activity suggests either misclassification in state and local procurement systems or genuinely limited demand for this specific pharmaceutical category among public jurisdictions.

Geographic spread across recent opportunities includes Florida, Texas, Minnesota, and Oregon through the cooperative purchasing vehicle, with no concentration in any single state or region. The most recent representative opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023), procuring naloxone and drug deactivation systems for community health initiatives with quarterly deliveries required; however, this is a supply purchase unrelated to antiviral chemistry. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) seeks generic multi-source pharmaceuticals and OTC products through authorized wholesalers and includes compliance with cGMP and DSCSA, but does not target antivirals specifically. The Texas HHS RFI (HHS0017013, April 3, 2026) explores direct-to-manufacturer pharmacy contracting strategy. If your firm manufactures or distributes antiviral isoquinolines to state and local health systems or correctional departments, this code warrants further investigation through state procurement portals directly, as recent indexed opportunities do not support it.